Unfit individuals also have the alternative of venetoclax moreover obinutuzumab (VO) as frontline therapy. This relies over a phase III demo that in contrast VO with ClbO in elderly/unfit patients.113 VO was outstanding in terms of reaction charge and progression-free survival, and experienced a similar safety profile. On this trial https://fredr763saj2.robhasawiki.com/user